Alnylam Pharmaceuticals (ALNY) on Sunday presented new analyses supporting the use of Amvuttra across a range of patients with transthyretin amyloidosis, including those already receiving Pfizer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results